MXPA06011218A - Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. - Google Patents
Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion.Info
- Publication number
- MXPA06011218A MXPA06011218A MXPA06011218A MXPA06011218A MXPA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A MX PA06011218 A MXPA06011218 A MX PA06011218A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- compound
- ppar
- disease
- invitrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55853304P | 2004-04-01 | 2004-04-01 | |
| PCT/US2005/010371 WO2005097098A2 (en) | 2004-04-01 | 2005-03-29 | Use of ppr delta agonists for treating demyelinating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06011218A true MXPA06011218A (es) | 2007-01-16 |
Family
ID=34977094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06011218A MXPA06011218A (es) | 2004-04-01 | 2005-03-29 | Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070149580A1 (https=) |
| EP (1) | EP1737440A2 (https=) |
| JP (1) | JP2007530703A (https=) |
| KR (1) | KR20060134191A (https=) |
| CN (1) | CN1950077A (https=) |
| AU (1) | AU2005231358A1 (https=) |
| BR (1) | BRPI0509540A (https=) |
| CA (1) | CA2561159A1 (https=) |
| IL (1) | IL178165A0 (https=) |
| MA (1) | MA28561B1 (https=) |
| MX (1) | MXPA06011218A (https=) |
| NO (1) | NO20064985L (https=) |
| RU (1) | RU2006138495A (https=) |
| SG (1) | SG138623A1 (https=) |
| WO (1) | WO2005097098A2 (https=) |
| ZA (1) | ZA200607850B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| JP5186217B2 (ja) * | 2005-11-28 | 2013-04-17 | 千寿製薬株式会社 | Ｐｐａｒアゴニスト含有医薬 |
| BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma, Inc. | ácidos fenóxi acéticos como ativadores de ppar delta |
| WO2007101864A2 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| MX2010013264A (es) | 2008-06-09 | 2011-02-25 | Sanofi Aventis | Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas. |
| WO2010000353A1 (en) | 2008-06-09 | 2010-01-07 | Sanofi-Aventis | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| US20120301463A1 (en) | 2009-09-30 | 2012-11-29 | President And Fellows Of Harvard College | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products |
| JP6068981B2 (ja) | 2009-12-17 | 2017-01-25 | サノフイ | ミエリン塩基性タンパク質プロモーターの制御下でルシフェラーゼを発現する動物モデル（ｍｂｐ−ｌｕｃｉ）、及び生物発光インビボ画像化のためのモデルの使用 |
| EP3502236B1 (en) * | 2011-02-18 | 2023-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| US20220387393A1 (en) * | 2019-11-06 | 2022-12-08 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997028149A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| AU2001288271A1 (en) * | 2000-08-17 | 2002-02-25 | Harrihar A. Pershadsingh | Methods for treating inflammatory diseases |
| GB0024361D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
| US20050020654A1 (en) * | 2003-03-15 | 2005-01-27 | Pershadsingh Harrihar A. | Novel PPAR agonists, pharmaceutical compositions and uses thereof |
| US20070037882A1 (en) * | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
-
2005
- 2005-03-29 JP JP2007506442A patent/JP2007530703A/ja not_active Abandoned
- 2005-03-29 BR BRPI0509540-9A patent/BRPI0509540A/pt not_active IP Right Cessation
- 2005-03-29 CN CNA2005800148506A patent/CN1950077A/zh active Pending
- 2005-03-29 KR KR1020067022955A patent/KR20060134191A/ko not_active Withdrawn
- 2005-03-29 SG SG200800123-2A patent/SG138623A1/en unknown
- 2005-03-29 AU AU2005231358A patent/AU2005231358A1/en not_active Abandoned
- 2005-03-29 MX MXPA06011218A patent/MXPA06011218A/es not_active Application Discontinuation
- 2005-03-29 CA CA002561159A patent/CA2561159A1/en not_active Abandoned
- 2005-03-29 RU RU2006138495/14A patent/RU2006138495A/ru not_active Application Discontinuation
- 2005-03-29 WO PCT/US2005/010371 patent/WO2005097098A2/en not_active Ceased
- 2005-03-29 EP EP05729215A patent/EP1737440A2/en not_active Withdrawn
-
2006
- 2006-09-18 IL IL178165A patent/IL178165A0/en unknown
- 2006-09-19 ZA ZA200607850A patent/ZA200607850B/xx unknown
- 2006-09-26 US US11/535,240 patent/US20070149580A1/en not_active Abandoned
- 2006-10-31 MA MA29427A patent/MA28561B1/fr unknown
- 2006-10-31 NO NO20064985A patent/NO20064985L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007530703A (ja) | 2007-11-01 |
| BRPI0509540A (pt) | 2007-09-18 |
| US20070149580A1 (en) | 2007-06-28 |
| ZA200607850B (en) | 2008-10-29 |
| CA2561159A1 (en) | 2005-10-20 |
| AU2005231358A1 (en) | 2005-10-20 |
| EP1737440A2 (en) | 2007-01-03 |
| IL178165A0 (en) | 2008-03-20 |
| WO2005097098A3 (en) | 2005-12-22 |
| CN1950077A (zh) | 2007-04-18 |
| NO20064985L (no) | 2006-10-31 |
| SG138623A1 (en) | 2008-01-28 |
| KR20060134191A (ko) | 2006-12-27 |
| MA28561B1 (fr) | 2007-04-03 |
| WO2005097098A2 (en) | 2005-10-20 |
| RU2006138495A (ru) | 2008-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Hes1 but not Hes5 regulates an astrocyte versus oligodendrocyte fate choice in glial restricted precursors | |
| Granneman et al. | Member of the peroxisome proliferator–activated receptor family of transcription factors is differentially expressed by oligodendrocytes | |
| MXPA06011218A (es) | Uso de agonistas del receptor delta activado por el proliferador de peroxisoma para el tratamiento de esclerosis multiple y otras enfermedades de desmielinizacion. | |
| EP4066826B1 (en) | Retinoic acid receptor gamma agonists for muscle repair and regeneration | |
| US20190099452A1 (en) | Methods for promoting oligodendrocyte regeneration and remyelination | |
| US20150119327A1 (en) | Drug screening platform for rett syndrome | |
| EP2806948B1 (en) | Method for enhancing remyelination using gli1 inhibitors | |
| Jana et al. | Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β | |
| WO2015069736A1 (en) | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS | |
| US20030082802A1 (en) | Method for neural stem cell differentiation using 5ht1a agonists | |
| US20170196839A1 (en) | Neurodegenerative diseases and methods of modeling | |
| Jana et al. | IL‐12 p40 homodimer, the so‐called biologically inactive molecule, induces nitric oxide synthase in microglia via IL‐12Rβ1 | |
| Yao et al. | In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes | |
| US20040092010A1 (en) | Method of proliferating and inducing brain stem cells to differentiate to neurons | |
| Zhang et al. | Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges | |
| Timmer et al. | The activin signaling pathway promotes differentiation of dI3 interneurons in the spinal neural tube | |
| EP3615022B1 (en) | Small organic molecules for use in the treatment of neuroinflammatory disorders | |
| AU2018420438A1 (en) | Treatment for demyelinating disease | |
| Hu et al. | The molecular events involved in oligodendrocyte precursor cell proliferation induced by the conditioned medium from B104 neuroblastoma cells | |
| HK40036876A (en) | Composition and method for muscle repair and regeneration | |
| HK40036876B (en) | Composition and method for muscle repair and regeneration | |
| Li | The mechanisms of ethanol-induced damage to the developing cerebellum: Effects on the cerebellar granule cells | |
| Van Heyningen | Control of glial progenitor cell number in the developing central nervous system | |
| Redwine | The in vivo PDGF response during remyelination in mouse spinal cord following murine hepatitis virus strain A59-induced transient demyelination | |
| HK1102384A (en) | Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |